Canagliflozin approved for type 2 diabetes

被引：2
|
作者：
Traynor, Kate
机构：
来源：
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY | 2013年 / 70卷 / 10期
关键词：
D O I：
10.2146/news130035
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
下载
收藏
页码：834 / 834
页数：1
相关论文
共 50 条
  • [41] Canagliflozin: A Review of Its Use in Patients with Type 2 Diabetes Mellitus
    Plosker, Greg L.
    DRUGS, 2014, 74 (07) : 807 - 824
  • [42] Canagliflozin, a Novel SGLT2 Inhibitor for Treatment of Type 2 Diabetes
    Nigro, Stefanie C.
    Riche, Daniel M.
    Pheng, Michelle
    Baker, William L.
    ANNALS OF PHARMACOTHERAPY, 2013, 47 (10) : 1301 - 1311
  • [43] Canagliflozin: A Novel SGLT2 Inhibitor for Type 2 Diabetes Mellitus
    Kaushal, Shaveta
    Singh, Harmanjit
    Thangaraju, Pugazhenthan
    Singh, Jasbir
    NORTH AMERICAN JOURNAL OF MEDICAL SCIENCES, 2014, 6 (03) : 107 - 113
  • [44] Type 2 Diabetes Canagliflozin Plus Metformin as Initial Therapy promising
    Ruchalla, Elke
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2016, 141 (09)
  • [45] EFFICACY AND SAFETY OF CANAGLIFLOZIN IN TYPE 2 DIABETES PATIENTS OF DIFFERENT ETHNICITY
    Davidson, Jaime A.
    Aguilar, Richard
    Lavalle Gonzalez, Fernando J.
    Trujillo, Angelina
    Alba, Maria
    Vijapurkar, Ujjwala
    Meininger, Gary
    ETHNICITY & DISEASE, 2016, 26 (02) : 221 - 228
  • [46] Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus
    Watts, Nelson B.
    Bilezikian, John P.
    Usiskin, Keith
    Edwards, Robert
    Desai, Mehul
    Law, Gordon
    Meininger, Gary
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2016, 101 (01): : 156 - 165
  • [47] Canagliflozin: A Review of Its Use in Patients with Type 2 Diabetes Mellitus
    Greg L. Plosker
    Drugs, 2014, 74 : 807 - 824
  • [48] Mediators of the effects of canagliflozin on kidney protection in patients with type 2 diabetes
    Li, JingWei
    Neal, Bruce
    Perkoyic, Vlado
    de Zeeuw, Dick
    Neuen, Brendon L.
    Arnott, Clare
    Simpson, Roger
    Oh, Richard
    Mahaffey, Kenneth W.
    Heerspink, Hiddo J. L.
    KIDNEY INTERNATIONAL, 2020, 98 (03) : 769 - 777
  • [49] Effects of canagliflozin on amputation risk in type 2 diabetes: the CANVAS Program
    Matthews, David R.
    Li, Qiang
    Perkovic, Vlado
    Mahaffey, Kenneth W.
    de Zeeuw, Dick
    Fulcher, Greg
    Desai, Mehul
    Hiatt, William R.
    Nehler, Mark
    Fabbrini, Elisa
    Kavalam, Mary
    Lee, Mary
    Neal, Bruce
    DIABETOLOGIA, 2019, 62 (06) : 926 - 938
  • [50] Cost Efficiency of Canagliflozin Versus Sitagliptin for Type 2 Diabetes Mellitus
    Ektare, Varun U.
    Lopez, Janice M. S.
    Martin, Silas C.
    Patel, Dipen A.
    Rupnow, Marcia F. T.
    Botteman, Marc F.
    AMERICAN JOURNAL OF MANAGED CARE, 2014, 20 (10): : S204 - S215
12345